Does Medical Cannabis Reduce Opioid Use in Adults With Pain
NCT ID: NCT04308148
Last Updated: 2024-03-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
217 participants
OBSERVATIONAL
2020-10-06
2024-03-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Medical Cannabis as an Opiate Alternative
NCT07194928
Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain
NCT04827992
Do Discounted Vouchers for Medical Cannabis Reduce Opioid Use in Adults With Pain
NCT04495725
Cannabis Vs Opioids Pain Management Objective Testing Comparisons
NCT03734731
Marijuana in Combination With Opioids in Palliative and Hospice Patients
NCT03233633
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* English or Spanish fluency
* Actively certified for medical cannabis
* Intends to have a soft-gel capsule product dispensed at Vireo
* Medical cannabis qualifying conditions or complications of "chronic or severe pain" or "pain that degrades health and functional capability as an alternative to opioid use or substance use disorder"
* Joint or neuropathic pain
* Current severe pain
* Dispensed opioid analgesics within the last 60 days
Exclusion Criteria
* Inability to complete study visits over 14 weeks
* Terminal illness
* Current or prior psychotic disorder
* Buprenorphine or methadone treatment for opioid use disorder within the past year
* Allergies to tapioca or coconut
* Currently pregnant, planning to become pregnant within the next 3 months, or breastfeeding
* Condition that is considered by a pharmacist or medical provider to be a contraindication to medical cannabis use (e.g. unstable cardiac arrhythmia or specific drug-use interaction)
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Laura and John Arnold Foundation
OTHER
Vireo Health
OTHER
Albert Einstein College of Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Julia Arnsten, MD, MPH
Role: PRINCIPAL_INVESTIGATOR
Albert Einstein College of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Montefiore Health System
The Bronx, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019-10029
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.